In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström’s Macroglobulinemia at EHA 2021
X4 Pharmaceuticals Presents Clinical Data Demonstrating Combinability of X4P-001-IO and Opdivo® (nivolumab) in Patients with Clear Cell Renal Cell Carcinoma